Redefining drug delivery.
NaDeNo enables nanoparticle therapeutics that combine local, targeted and controlled delivery of hard-to-deliver molecules. Our lead asset, PACAB-002, is designed to prevent recurrence in ovarian cancer by eradicating residual peritoneal micrometastases, and is planned to enter Phase 1 clinical investigation in early 2027.
Our platform is available for pharma and biotech companies with hard-to-deliver molecules where improved formulation, local retention, targeting or controlled release unlock may therapeutic value
Drug compatibility
Encapsulation of hydrophobic and hard-to-deliver molecules across relevant drug classes.
Scalable manufacturing
Patented one-step encapsulation process without chemical modification of the API.
Targeting
Chemical or biological targeting through adaptable nanoparticle surface properties.
Retention & release
Prolonged local retention combined with controlled release for sustained exposure.
Lead asset
PACAB-002 is designed to prevent recurrence in ovarian cancer
NaDeNo’s platform-enabled lead candidate PACAB-002 will start clinical investigation in a Phase I trial beginning early 2027.
PACAB-002 is intended to eradicate peritoneal micrometastases for patients with high-grade serous ovarian cancer (HGSOC), the leading cause of high recurrence and poor survival.
The European Medicines Agency (EMA) has granted orphan drug designation to PACAB-002, a recognition of the strong preclinical efficacy data and its potential to provide a clinically relevant benefit over existing treatment options in ovarian cancer.
News
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.